RVALL / Reva Medical Inc - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 04)* REVA Medical, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) (CUS

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 04)* REVA Medical, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) U8000C103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

RVA / REVA Medical, Inc. 15-12G - - 15-12G

15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-54192 REVA Medical, Inc. (Exact name of registrant as specified i

Financial Statements and Exhibits, Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2020 REVA Medical, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-54192 33-0810505 (State or Other Jurisdiction of Incorporation) (Commissio

Order of the Bankruptcy Court, dated February 19, 2020, confirming the Prepackaged Chapter 11 Plan of REVA Medical, Inc.

EX-2.1 2 d887965dex21.htm EX-2.1 Case 20-10072-JTD Doc 114 Filed 02/19/20 Page 1 of 50 Exhibit 2.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: Chapter 11 REVA MEDICAL, INC., Case No. 20-10072 (JTD) Debtor.1 Re D.I.: 13, 14, 42, 82, 97, 98, and 105 FINDINGS OF FACT, CONCLUSIONS OF LAW, AND ORDER (I) APPROVING THE DEBTOR’S (A) DISCLOSURE STATEMENT PURSUANT TO SECTIONS 1

REVA Medical Successfully Completes Financial Restructuring

EX-99.1 Exhibit 99.1 REVA Medical Successfully Completes Financial Restructuring San Diego, California (Wednesday, March 4, 2020) – REVA Medical, Inc. (“REVA” or the “Company”) announced today that the Company emerged from Chapter 11 bankruptcy protection on February 26, 2020, successfully completing its financial restructuring process and implementing its plan of reorganization (the “Plan”), whic

RVA / REVA Medical, Inc. S-8 POS - - S-8 POS

S-8 POS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-223496 TO FORM S-8 REGISTRATION STATEMENT NO. 333-216293 TO FORM S-8 REGISTRATION STATEMENT NO. 333-210084 TO FORM S-8 REGISTRATION STATEMENT NO. 333-203103 TO FORM S-8 REGISTRATION STATEMENT NO. 333-194619 TO FORM S-8 REGISTRATION STATEMENT NO.

RVA / REVA Medical, Inc. S-8 POS - - S-8 POS

S-8 POS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-223496 TO FORM S-8 REGISTRATION STATEMENT NO. 333-216293 TO FORM S-8 REGISTRATION STATEMENT NO. 333-210084 TO FORM S-8 REGISTRATION STATEMENT NO. 333-203103 TO FORM S-8 REGISTRATION STATEMENT NO. 333-194619 TO FORM S-8 REGISTRATION STATEMENT NO.

RVA / REVA Medical, Inc. S-8 POS - - S-8 POS

S-8 POS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-223496 TO FORM S-8 REGISTRATION STATEMENT NO. 333-216293 TO FORM S-8 REGISTRATION STATEMENT NO. 333-210084 TO FORM S-8 REGISTRATION STATEMENT NO. 333-203103 TO FORM S-8 REGISTRATION STATEMENT NO. 333-194619 TO FORM S-8 REGISTRATION STATEMENT NO.

RVA / REVA Medical, Inc. S-8 POS - - S-8 POS

S-8 POS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-223496 TO FORM S-8 REGISTRATION STATEMENT NO. 333-216293 TO FORM S-8 REGISTRATION STATEMENT NO. 333-210084 TO FORM S-8 REGISTRATION STATEMENT NO. 333-203103 TO FORM S-8 REGISTRATION STATEMENT NO. 333-194619 TO FORM S-8 REGISTRATION STATEMENT NO.

RVA / REVA Medical, Inc. S-8 POS - - S-8 POS

S-8 POS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-223496 TO FORM S-8 REGISTRATION STATEMENT NO. 333-216293 TO FORM S-8 REGISTRATION STATEMENT NO. 333-210084 TO FORM S-8 REGISTRATION STATEMENT NO. 333-203103 TO FORM S-8 REGISTRATION STATEMENT NO. 333-194619 TO FORM S-8 REGISTRATION STATEMENT NO.

RVA / REVA Medical, Inc. S-8 POS - - S-8 POS

S-8 POS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-223496 TO FORM S-8 REGISTRATION STATEMENT NO. 333-216293 TO FORM S-8 REGISTRATION STATEMENT NO. 333-210084 TO FORM S-8 REGISTRATION STATEMENT NO. 333-203103 TO FORM S-8 REGISTRATION STATEMENT NO. 333-194619 TO FORM S-8 REGISTRATION STATEMENT NO.

RVA / REVA Medical, Inc. S-8 POS - - S-8 POS

S-8 POS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-223496 TO FORM S-8 REGISTRATION STATEMENT NO. 333-216293 TO FORM S-8 REGISTRATION STATEMENT NO. 333-210084 TO FORM S-8 REGISTRATION STATEMENT NO. 333-203103 TO FORM S-8 REGISTRATION STATEMENT NO. 333-194619 TO FORM S-8 REGISTRATION STATEMENT NO.

RVA / REVA Medical, Inc. S-8 POS - - S-8 POS

S-8 POS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-223496 TO FORM S-8 REGISTRATION STATEMENT NO. 333-216293 TO FORM S-8 REGISTRATION STATEMENT NO. 333-210084 TO FORM S-8 REGISTRATION STATEMENT NO. 333-203103 TO FORM S-8 REGISTRATION STATEMENT NO. 333-194619 TO FORM S-8 REGISTRATION STATEMENT NO.

RVA / REVA Medical, Inc. / JP Morgan Chase & Co - FILING REVA MEDICAL, INC. Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 03)* REVA MEDICAL, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) U8000C103 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Bankruptcy or Receivership

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 14, 2020 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission

Restructuring Support Agreement, dated December 23, 2019 by and between the debtors and the Supporting Lenders

EX-10.1 Exhibit 10.1 Execution Version *** Portions have been Redacted THIS RESTRUCTURING SUPPORT AGREEMENT IS NOT AN OFFER OR ACCEPTANCE WITH RESPECT TO ANY SECURITIES OR A SOLICITATION OF ACCEPTANCES OF A CHAPTER 11 PLAN WITHIN THE MEANING OF SECTION 1125 OF THE BANKRUPTCY CODE. ANY SUCH OFFER OR SOLICITATION WILL COMPLY WITH ALL APPLICABLE SECURITIES LAWS AND/OR PROVISIONS OF THE BANKRUPTCY COD

REVA Medical Files for Court Approval of Prepackaged Plan of Reorganization

EX-99.1 Exhibit 99.1 REVA Medical Files for Court Approval of Prepackaged Plan of Reorganization Sydney, Australia and San Diego, California (Wednesday, 15 January 2020 AEST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) announced today that it has filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court in Delaware. Prior

Financial Statements and Exhibits, Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 13, 2019 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commissio

Corporate Update

EX-99.1 2 d849206dex991.htm EX-99.1 Exhibit 99.1 Corporate Update San Diego, California (Friday, 13 December 2019) – REVA Medical, Inc. (“REVA” or the “Company”) has not been successful in securing additional financing to continue long term operations. The Company’s unaudited outstanding current accounts payable is $1.2 million and cash balance is $1.3 million. The Company’s revenue projections fo

REVA Receives Additional Interim Funding

Exhibit 99.1 REVA Receives Additional Interim Funding Sydney, Australia and San Diego, California (Monday, 5 August 2019 - AEST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) said today that it has received an additional $1.2 million in funding as part of the April 2019 Senior Secured Credit Facility to continue to support operations on an interim basis. The funding is a Multi-Draw Ter

First Amendment to Credit and Guaranty Agreement

Execution Version Exhibit 10.1 Certain identified information has been omitted from this document because it is both not material and would be competitively harmful if publicly disclosed, and had been marked with “[***]” to indicate where omissions have been made. FIRST AMENDMENT TO CREDIT AND GUARANTY AGREEMENT This FIRST AMENDMENT TO CREDIT AND GUARANTY AGREEMENT (this “Amendment”), dated as of

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 6, 2019 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File

Credit and Guaranty Agreement by and between Goldman Sachs International, Various Lenders and the Company, dated April 2, 2019

Exhibit 10.2 Execution Version Certain identified information has been omitted from this document because it is both not material and would be competitively harmful if publicly disclosed, and had been marked with “[***]” to indicate where omissions have been made. CREDIT AND GUARANTY AGREEMENT dated as of April 2, 2019 among REVA MEDICAL, INC., as Company, VARIOUS LENDERS, and GOLDMAN SACHS INTERN

REVA Receives Interim Funding and Enters into an Amendment to License Agreement with Rutgers, The State University of New Jersey

Exhibit 99.1 REVA Receives Interim Funding and Enters into an Amendment to License Agreement with Rutgers, The State University of New Jersey Sydney, Australia and San Diego, California (Monday, 8 April 2019 - AEDT) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) said today that as indicated in its ASX announcement dated 25 March 2019, it has now executed a Credit and Guaranty Agreement

Amendment #5 dated April 2, 2019 to the Exclusive License Agreement Number 2, by and between Rutgers, The State University of New Jersey and the Company, dated July 30, 2018

Exhibit 10.1 AMENDMENT #5 TO EXCLUSIVE LICENSE AGREEMENT #2 THIS AMENDMENT #5 TO EXCLUSIVE LICENSE AGREEMENT #2 (the "Amendment #5") is entered into as of April 2, 2019 ("Amendment Effective Date"), by and between Reva Medical Inc. ("Licensee") and Rutgers, The State University of New Jersey ("Rutgers"). WHEREAS, Licensee and Rutgers have entered into an exclusive license agreement effective July

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 2, 2019 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File N

Pledge and Security Agreement by and between Goldman Sachs International, Various Lenders and the Company, dated April 2, 2019

Exhibit 10.3 Execution Version Certain identified information has been omitted from this document because it is both not material and would be competitively harmful if publicly disclosed, and had been marked with “[***]” to indicate where omissions have been made. PLEDGE AND SECURITY AGREEMENT dated as of April 2, 2019 by and among EACH OF THE GRANTORS PARTY HERETO and GOLDMAN SACHS INTERNATIONAL,

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 29, 2019 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File

REVA RECEIVES INTERIM FUNDING COMMITMENT AND ANNOUNCES LEADERSHIP CHANGES

EX-99.1 2 rva-ex9916.htm EX-99.1 Exhibit 99.1 REVA RECEIVES INTERIM FUNDING COMMITMENT AND ANNOUNCES LEADERSHIP CHANGES Sydney, Australia and San Diego, California (Monday, 25 March 2019 - AEDT) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) said today that it has secured a letter of commitment for up to $3 million of debt financing to fund operations on an interim basis. The funding wi

REVA CONTINUES SuspenSion of Trading

EX-99.1 2 rva-ex9916.htm EX-99.1 Exhibit 99.1 REVA CONTINUES SuspenSion of Trading San Diego, California (Tuesday, March 12, 2019 - PST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) voluntarily suspended trading on 24 February 2019 while in discussions with representatives of certain major debt and equity holders to address (i) the Company’s immediate financial needs and (ii) the Comp

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 12, 2019 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 5, 2019 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File N

REVA ANNOUNCES EXTENSION TO VOLUNTARY SUSPENSION OF TRADING

EX-99.1 2 rva-ex9916.htm EX-99.1 Exhibit 99.1 REVA ANNOUNCES EXTENSION TO VOLUNTARY SUSPENSION OF TRADING San Diego, California (Tuesday, March 5, 2019 - PST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) said today that on 6 March 2019 (AEDT), the Australian Securities Exchange issued a market announcement indicating that the securities of the Company will remain suspended from quotat

REVA ANNOUNCES EXTENSION TO VOLUNTARY SUSPENSION OF TRADING

EX-99.1 2 rva-ex9916.htm EX-99.1 Exhibit 99.1 REVA ANNOUNCES EXTENSION TO VOLUNTARY SUSPENSION OF TRADING San Diego, California (Sunday, February 24, 2019 - PST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) said today that on 25 February 2019 (AEDT), the Australian Securities Exchange issued a market announcement indicating that the securities of the Company will remain suspended from

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 25, 2019 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission Fi

REVA ANNOUNCES VOLUNTARY SUSPENSION OF TRADING

Exhibit 99.1 REVA ANNOUNCES VOLUNTARY SUSPENSION OF TRADING San Diego, California (Tuesday, February 19, 2019 - PST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) said today that on 20 February 2019 (AEDT), the Australian Securities Exchange issued a market announcement indicating that the securities of the Company will be suspended from quotation immediately at the Company’s request u

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 19, 2019 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission Fi

REVA ANNOUNCES TRADING HALT

EX-99.1 2 rva-ex9916.htm EX-99.1 Exhibit 99.1 REVA ANNOUNCES TRADING HALT San Diego, California (Sunday, February 17, 2019 - PST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) said today that on 18 February 2019 (AEDT), the Australian Securities Exchange issued a market announcement indicating that the securities of the Company have been placed in a trading halt at our request through

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 17, 2019 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission Fi

RVA / REVA Medical, Inc. / Senrigan Capital Group Ltd - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) REVA Medical, Inc. (Name of Issuer) Common Stock, par value .0001 per share (Title of Class of Securities) 76133E109 (CUSIP Number) June 29,

RVA / REVA Medical, Inc. / BROOKSIDE CAPITAL MANAGEMENT LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Reva Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 76133E109 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc

JOINT ACQUISTION AGREEMENT PURSUANT TO RULE 13d-1(k)

EX-99.1 2 a19-45631ex99d1.htm EX-99.1 EXHIBIT 99.1 JOINT ACQUISTION AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional j

REVA ANNOUNCES REDUCTION IN FORCE

EX-99.1 2 rva-ex9916.htm EX-99.1 EXHIBIT 99.1 REVA ANNOUNCES REDUCTION IN FORCE Sydney, Australia and San Diego, California (Tuesday, 5 February 2019 - AEDT) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced it is realigning the organization to align with current business conditions. Effective 8 February 2

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 4, 2019 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission Fil

Executive Employment Agreement, effective as of January 4, 2019, by and between the Company and Leigh Elkolli.

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is made effective as of January 4, 2019 (the “Effective Date”), by and between REVA Medical, Inc. (the “Company”) and Leigh F. Elkolli (the “Executive”). The parties agree as follows: 1.Employment. The Company hereby employs Executive, and Executive hereby accepts such employment, upon the terms and

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 14, 2019 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission Fil

BNVI / BioNovo, Inc. / JP Morgan Chase & Co - NONE Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* REVA MEDICAL, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) U8000C103 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 2, 2019 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File

Leigh Elkolli Promoted to Chief Financial Officer

Exhibit 99.1 Leigh Elkolli Promoted to Chief Financial Officer Sydney, Australia and San Diego, California (Friday, 4 January 2019 - AEDT) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced the promotion of Leigh Elkolli to the position of Chief Financial Officer and Corporate Secretary, effective January 4

Important Notice Not an Offer for Securities This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial product advic

REVA Medical Corporate Presentation November 2018 ©2018 REVA Medical CC100021 Rev.

Regulation FD Disclosure, Financial Statements and Exhibits

8-K 1 rva-8k20181114.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 14, 2018 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K 1 rva-8k20181105.htm 8-K - PERSONNEL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 5, 2018 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other juris

RVA / REVA Medical, Inc. Q3 2018 10-Q (Quarterly Report)

10-Q 1 rva-10q20180930.htm Q3 2018 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission

REVA MEDICAL REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS

EX-99.1 2 rva-ex9918.htm EX-99.1 Exhibit 99.1 REVA MEDICAL REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS San Diego, California and Sydney, Australia (Tuesday, 6 November 2018 - AEDT) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular medical applications, today provided a business update and reported financial results for the third

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 rva-8k20180930.htm 8-K - ER Q3 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 5, 2018 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other juri

Regulation FD Disclosure, Financial Statements and Exhibits

8-K 1 rva-8k20180922.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: September 22, 2018 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of

Disclosure Statement of Financial Interest Speaker or Advisory Honoraria from Biotronik, Abbott, REVA.

EX-99.4 5 rva-ex99419.htm EX-99.4 On-going Activities with a Radiopaque Tyrosine-Carbonate-Based Polymeric BRS: Fantom Ulf Landmesser, MD Charité – Universitatsmedizin Berlin, Berlin, Germany Exhibit 99.4 Disclosure Statement of Financial Interest Speaker or Advisory Honoraria from Biotronik, Abbott, REVA. Lessons Learned from 1st Generation BRS Importance of implant technique Selecting the right

Presentation entitled “Two-year healing patterns after implantation of the FANTOM bioresorbable scaffold”

EX-99.3 4 rva-ex99318.htm EX-99.3 Exhibit 99.3

Presentation entitled “FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – 24-Month Follow-Up Clinical Outcomes Final Results”

Exhibit 99.2

Presentation entitled “Primary PCI in STEMI with sirolimus eluting FANTOM bioresorbable vascular scaffold first guided with optical coherence tomography – acute results from a FANTOM STEMI pilot study”

Exhibit 99.1

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 7, 2018 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File

REVA MEDICAL REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS

Exhibit 99.1 REVA MEDICAL REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS San Diego, California and Sydney, Australia (Tuesday, 7 August 2018 - AEST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular medical applications, today provided a business update and reported financial results for the second quarter ended June 30, 2018. “In

RVA / REVA Medical, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54192 REVA MEDICAL, INC. (E

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 30, 2018 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission Fi

Amendment #4 to Exclusive License Agreement Number 2, by and between Rutgers, the State University of New Jersey and the Company, dated July 30, 2018

EX-10.1 2 d603472dex101.htm EX-10.1 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETED ASTERISKS [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. AMENDMENT #4 TO EXCLUSIVE LICENSE AGREEMENT #2 THIS AMENDMENT #4 TO EXCLUSIVE LICENSE AGREEMENT

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 30, 2018 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File N

REVA Medical Provides Quarterly Cashflow Report for the Quarter Ended 30 June 2018

EX-99.1 2 rva-ex9916.htm EX-99.1 Exhibit 99.1 REVA Medical Provides Quarterly Cashflow Report for the Quarter Ended 30 June 2018 San Diego, California and Sydney, Australia (Monday, 30 July 2018 - AEST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular medical applications, is pleased to provide the attached Appendix 4C Quarterly

Financial Statements and Exhibits

8-K 1 rva-8k20180725.htm 8-K MOTIV APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 25, 2018 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other juris

REVA ENTERS PERIPHERAL ARTERY DISEASE SPACE WITH FIRST-EVER CE MARK OF A BIORESORBALE SCAFFOLD FOR BELOW THE KNEE THERAPY

Exhibit 99.1 REVA ENTERS PERIPHERAL ARTERY DISEASE SPACE WITH FIRST-EVER CE MARK OF A BIORESORBALE SCAFFOLD FOR BELOW THE KNEE THERAPY Sydney, Australia and San Diego, California (Thursday, 26 July 2018 - AEST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, today announced that its MOTIV™ bioresorbable scaffold i

Regulation FD Disclosure, Financial Statements and Exhibits

8-K 1 rva-8k20180626.htm 8-K INVESTOR MTGS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 26, 2018 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisd

Important Notice Not an Offer for Securities This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial product advic

REVA Medical Corporate Presentation June 2018 ©2018 REVA Medical CC100021 Rev. H Exhibit 99.1 Important Notice Not an Offer for Securities This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial product advice nor take into account your investment objectives, taxa

FANTOM’S POSITIVE TWO-YEAR RESULTS SHOW SUSTAINED SAFETY AND EFFICACY

Exhibit 99.1 FANTOM’S POSITIVE TWO-YEAR RESULTS SHOW SUSTAINED SAFETY AND EFFICACY San Diego, California (Wednesday, May 23, 2018 - PDT) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, reported sustained safety and efficacy of the Fantom® bioresorbable scaffold (“BRS”) through two years based on data from the FANT

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 23, 2018 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File Nu

Speaker's name: Alexandre Abizaid, MD x I have the following potential conflicts of interest to report: None Potential conflicts of interest

New 24-month data from the FANTOM II clinical trial Dr. Alexandre Abizaid Instituto Dante Pazzanese de Cardiologia Sao Paulo, Brazil Exhibit 99.1 Speaker's name: Alexandre Abizaid, MD x I have the following potential conflicts of interest to report: None Potential conflicts of interest Second Generation Fantom Bioresorbable Scaffold Sirolimus Scaffold Design Delivery System Thin struts: 125 µm Enh

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 23, 2018 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File Nu

The FANTOM BRS Desaminotyrosine based polycarbonate backbone Strut thickness 125µm Sirolimus eluting for 3 months Full resorption within 3-4 years FANTOM II

REVA FANTOM II Performance and healing patterns by OCT Two-year serial follow-up Emil Nielsen Holck, Jo Simonsen, Didier Carrié, Nobert Frey, Matthias Lutz, Joachim Weber-Albers, Darius Dudek, Bernard Chevalier, Jouke Dijkstra, Jens Lassen, Jeffrey Anderson, Joest daemen, Evald Høj Christiansen, Alexandre Abizaid, Niels Ramsing Holm On behalf of the FANTOM II investigators Niels Ramsing Holm Aarhus University Hospital, Denmark Exhibit 99.

Speaker's name : Gregor Leibundgut I have the following potential conflicts of interest to report: Receipt of honoraria or consultation fees: REVA Medical Potential conflicts of interest

Tyrocore: a proprietary polymer uniquely designed for vascular scaffolds PD Dr. med Gregor Leibundgut Medizinische Universitätsklinik Kantonsspital Baselland Liestal, Switzerland Exhibit 99.2 Speaker's name : Gregor Leibundgut I have the following potential conflicts of interest to report: Receipt of honoraria or consultation fees: REVA Medical Potential conflicts of interest Limited use of first

Potential conflicts of interest Speaker's name : Matthias, Lutz, Kiel ☑ I have the following potential conflicts of interest to report: Receipt of honoraria or consultation fees: Abbott, REVA Medical

Fantom Encore case review and introduction to the REVA Technique Dr. med Matthias Lutz Universitätsklinikum Schleswig-Holstein Kiel, Germany Exhibit 99.4 Potential conflicts of interest Speaker's name : Matthias, Lutz, Kiel ☑ I have the following potential conflicts of interest to report: Receipt of honoraria or consultation fees: Abbott, REVA Medical Implant Technique Matters Bioresorbable Scaffo

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 16, 2018 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File Nu

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 16, 2018 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File Nu

Important Notice Not an Offer for Securities This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial product advic

REVA Medical Corporate Presentation May 2018 ©2018 REVA Medical CC100021 Rev. F Exhibit 99.1 Important Notice Not an Offer for Securities This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial product advice nor take into account your investment objectives, taxat

RVA / REVA Medical, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54192 REVA MEDICAL, INC. (

RVA / REVA Medical, Inc. DEFA 14A

DEFA14A 1 rva-defa14a20180516.htm DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by

RVA / REVA Medical, Inc. DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☑ Definitive Proxy State

RVA / REVA Medical, Inc. PRE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☑ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 22, 2018 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 13, 2018 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File

Important Notice Not an Offer for Securities This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial product advic

REVA Medical Corporate Presentation March 2018 ©2018 REVA Medical CC100021 Rev. E Exhibit 99.1 Important Notice Not an Offer for Securities This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial product advice nor take into account your investment objectives, tax

ASX:RVA / REVA MEDICAL, INC S-8

As filed with the Securities and Exchange Commission on March 7, 2018 Registration No.

REVA MEDICAL REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS Demonstrates Early Commercial Progress of the Fantom Bioresorbable Scaffold

EX-99.1 2 rva-ex9917.htm EX-99.1 Exhibit 99.1 REVA MEDICAL REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS Demonstrates Early Commercial Progress of the Fantom Bioresorbable Scaffold San Diego, California (Wednesday, March 7, 2017, PST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular medical applications, today repo

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 7, 2018 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File N

Form of Restricted Stock Unit Agreement (2010 Equity Incentive Plan)*

Exhibit 10.5(c) REVA MEDICAL, INC. RESTRICTED STOCK UNITS AGREEMENT Reva Medical, Inc. (the “Company”) has granted to the Participant named in the Notice of RSU Award (the “Award Notice”), to which this Restricted Stock Units Agreement (the “Agreement”) is attached, an Award consisting of Restricted Stock Units (“RSUs”) subject to the terms and conditions set forth in the Award Notice and this Agr

Composite Bylaws

COMPOSITE BYLAWS OF REVA MEDICAL, INC. (a Delaware Corporation) Article I Exhibit 3.2 Stockholders Section 1.Annual Meetings. The annual meeting of stockholders of REVA Medical, Inc. (the “Corporation”) for the election of directors and for the transaction of such other business as may properly come before the meeting shall be held each fiscal year at such date and time, within or without the Stat

Form of Restricted Stock Agreement (2010 Equity Incentive Plan)*

Exhibit 10.5(d) REVA MEDICAL, INC. RESTRICTED STOCK AGREEMENT REVA Medical, Inc. (the “Company”) has granted to the Participant named in the Notice of Grant of Restricted Stock (the “Grant Notice”) to which this Restricted Stock Agreement (the “Agreement”) is attached an Award consisting of Shares subject to the terms and conditions set forth in the Grant Notice and this Agreement. The Award has b

ASX:RVA / REVA MEDICAL, INC 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-54192 REVA MEDICAL, INC. (Exact name of registrant as specified i

Consulting Agreement, dated July 5, 2017, by and between REVA Medical, Inc. and Brandi L. Roberts

EX-10.18 5 rva-ex1018549.htm EX-10.18 Exhibit 10.18 Consulting Agreement This Consulting Agreement (the “Agreement”) is made and entered into as of the 5th day of July, 2017 (the “Effective Date”), by and between Reva Medical, Inc., a Delaware corporation, with its principal place of business located at 5751 Copley Drive, Suite B, San Diego, CA 92111 (“Company”) and the individual or entity design

Consulting Agreement, dated July 13, 2017, by and between REVA Medical, Inc. and Robert K. Schultz

Exhibit 10.19 Consulting Agreement This Consulting Agreement (“Agreement”) is made and entered into as of July 13, 2017 (“Effective Date”) by and between REVA Medical, Inc., a Delaware corporation, with its principal place of business located at 5751 Copley Dr., San Diego, CA 92111 (“Company”) and Robert K. Schultz (“Consultant”). Recitals Whereas, Consultant has unique skills and knowledge in Com

Consulting Agreement, dated September 11, 2017, by and between REVA Medical, Inc. and Katrina L. Thompson

EX-10.20 7 rva-ex1020481.htm EX-10.20 Exhibit 10.20 Consulting Agreement This Consulting Agreement (“Agreement”) is made and entered into as of September 11, 2017 (“Effective Date”) by and between REVA Medical, Inc., a Delaware corporation, with its principal place of business located at 5751 Copley Dr., San Diego, CA 92111 (“Company”) and Katrina L. Thompson (“Consultant”). Recitals Whereas, Cons

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 28, 2018 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission Fi

Preliminary Final Report on Appendix 4E Year Ended 31 December 2017

Exhibit 99.1 Preliminary Final Report on Appendix 4E Year Ended 31 December 2017 Sydney, Australia and San Diego, California (Wednesday, 28 February 2017, AEDT) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular medical applications, is pleased to release its preliminary financial report for the year ended 31 December 2017 (the “R

RVA / REVA Medical, Inc. / BROOKSIDE CAPITAL MANAGEMENT LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Reva Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 76133E109 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc

JOINT ACQUISTION AGREEMENT PURSUANT TO RULE 13d-1(k)

EXHIBIT 99.1 JOINT ACQUISTION AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The under

RVA / REVA Medical, Inc. / Senrigan Capital Group Ltd - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) REVA Medical, Inc. (Name of Issuer) Common Stock, par value .0001 per share (Title of Class of Securities) 76133E109 (CUSIP Number) June 16,

REVA ANNOUNCES APPOINTMENT OF STEPHEN OESTERLE, MD TO BOARD OF DIRECTORS

rva-ex9917.htm Exhibit 99.1 REVA ANNOUNCES APPOINTMENT OF STEPHEN OESTERLE, MD TO BOARD OF DIRECTORS San Diego, California (Monday, February 5, 2018 - PST) ? REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?), a leader in bioresorbable polymer technologies for vascular applications, announces the appointment of Stephen Oesterle, MD to its Board of Directors, effective immediately. Dr. Oesterl

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

rva-8k20180205.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 5, 2018 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporati

Important Notice Not an Offer for Securities This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial product advic

rva-ex9918.pptx.htm REVA Medical Corporate Presentation January 2018 ?2017 REVA Medical CC100021 Rev. D Exhibit 99.1 Important Notice Not an Offer for Securities This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial product advice nor take into account your inve

Regulation FD Disclosure, Financial Statements and Exhibits

rva-8k20180108.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 8, 2018 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporatio

BNVI / BioNovo, Inc. / JP Morgan Chase & Co - NONE Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* REVA MEDICAL, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) U8000C103 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des

Important Notice Not an Offer for Securities This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial product advic

rva-ex991150.pptx.htm REVA Medical Corporate Presentation November 2017 ?2017 REVA Medical CC100021 Rev. C Exhibit 99.1 Important Notice Not an Offer for Securities This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial product advice nor take into account your i

Regulation FD Disclosure, Financial Statements and Exhibits

rva-8k20171127.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 27, 2017 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporat

Important Notice Not an Offer for Securities This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial product advic

rva-ex9917.pptx.htm REVA Medical Corporate Presentation November 2017 ?2017 REVA Medical CC100021 Rev. B Exhibit 99.1 Important Notice Not an Offer for Securities This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial product advice nor take into account your inv

Regulation FD Disclosure, Financial Statements and Exhibits

rva-8k20171108.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 8, 2017 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporati

Financial Statements and Exhibits, Results of Operations and Financial Condition

rva-8k20171107.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 7, 2017 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporati

REVA MEDICAL REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS

rva-ex9916.htm Exhibit 99.1 REVA MEDICAL REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS San Diego, California (Tuesday, November 7, 2017, PST) ? REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?), a leader in bioresorbable polymer technologies for vascular medical applications, today reported financial results for the quarter ended September 30, 2017. Third Quarter 2017 Operating Results The Co

ASX:RVA / REVA MEDICAL, INC 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54192 REVA MEDICAL, IN

Sixth Amendment to Telecom Business Center NNN Lease between Gildred Building Company and REVA Medical, Inc.

Exhibit 10.2 SIXTH AMENDMENT TO TELECOM BUSINESS CENTER NNN LEASE THIS SIXTH AMENDMENT TO TELECOM BUSINESS CENTER NNN LEASE ("Amendment"), dated for reference purposes only as of October 5, 2017, is entered into by and between GILDRED BUILDING COMPANY, a California corporation, doing business as Campus at Copley (“Landlord”), as successor in interest to HB COPLEY BUSINESS CENTER, LLC, a Delaware l

Executive Employment Agreement, dated August 28, 2017 by and between REVA Medical, Inc. and Brandi L. Roberts

EX-10.1 2 rva-ex101209.htm EX-10.1 Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is made effective as of August 28, 2017 (the “Effective Date”), by and between REVA Medical, Inc. (the “Company”) and Brandi Roberts (the “Executive”). The parties agree as follows: 1.Employment. The Company hereby employs Executive, and Executive hereby accepts suc

REVA MEDICAL 8-K (Current Report/Significant Event)

rva-8k20171031.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 31, 2017 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporati

Disclosure Statement of Financial Interest Grant/Research Support Consulting Fees/Honoraria Edwards, Medtronic, Abbott, BSC Edwards, Medtronic, Abbott, BSC Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or

rva-ex991133.pptx.htm James Hermiller, MD, FACC, MSCAI St Vincent Medical Group St Vincent Heart Center of Indiana Indianapolis, IN DIDACTIC SESSION: BIORESORBABLE VASCULAR SCAFFOLDS, PART 1 - DEVICES AND EMERGING DATA Colorado Convention Center, Mile High Ballroom 4E-4F, Ballroom Level Tuesday, October 31, 4:43 PM - 4:53 PM Session III. Next Generation Scaffolds Part 1: Design Iterations, Data, a

Regulation FD Disclosure, Financial Statements and Exhibits

rva-8k20171031.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 31, 2017 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporati

Presentation entitled “FANTOM II Trial: First Report on Initial 24 Month Outcomes”

rva-ex9916.pptx.htm TCT 332: FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold ? First Report on Initial 24 Month Outcomes Fantom II Clinical Trial Investigators Exhibit 99.1

Appendix 4C Quarter Ended 30 September 2017

EX-99.1 2 rva-ex9918.htm EX-99.1 Exhibit 99.1 Appendix 4C Quarter Ended 30 September 2017 San Diego, California and Sydney, Australia (Tuesday, 31 October, 2017, AEST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular medical applications, is providing the attached Appendix 4C Quarterly Report for the quarter ended 30 September 2

Financial Statements and Exhibits, Results of Operations and Financial Condition

rva-8k20171031.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 31, 2017 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporati

Important Notice Not an Offer for Securities This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial product advic

rva-ex99115.pptx.htm REVA Medical Corporate Presentation October 2017 ©2017 REVA Medical CC100021 Rev. A Exhibit 99.1 Important Notice Not an Offer for Securities This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial product advice nor take into account your inv

Regulation FD Disclosure, Financial Statements and Exhibits

rva-8k20171011.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 11, 2017 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporati

ASX:RVA / REVA MEDICAL, INC 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54192 REVA MEDICAL, INC. (Exa

REVA MEDICAL BSC DISTRIBUTION OPTION LAPSES (Current Report/Significant Event)

rva-8k20170803.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 3, 2017 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation

Boston Scientific’s Distribution Option Lapses

rva-ex9916.htm EXHIBIT 99.1 Boston Scientific?s Distribution Option Lapses San Diego, California and Sydney, Australia (Friday, 4 August 2017 AEST) ? REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) announces the expiration of Boston Scientific Corporation?s (?BSC?) exclusive right to negotiate for distribution of REVA?s coronary and peripheral bioresorbable scaffolds. BSC?s right to negoti

Financial Statements and Exhibits, Results of Operations and Financial Condition

rva-8k20170730.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 30, 2017 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation)

Appendix 4C Quarter Ended 30 June 2017

rva-ex9916.htm EXHIBIT 99.1 Appendix 4C Quarter Ended 30 June 2017 San Diego, California and Sydney, Australia (Monday, 31 July 2017 AEST) ? REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) is pleased to provide the attached Appendix 4C Quarterly Report for the quarter ended 30 June 2017. The Appendix 4C is unaudited. Second Quarter Highlights During the second quarter of 2017, the Company

REVA MEDICAL ORGANIZATIONAL CHANGES 7-13-17 (Current Report/Significant Event)

rva-8k20170713.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 13, 2017 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation)

REVA Announces Organizational Changes Commercial Rollout of Fantom Progressing in Europe

EX-99.1 2 rva-ex9916.htm EX-99.1 EXHIBIT 99.1 REVA Announces Organizational Changes Commercial Rollout of Fantom Progressing in Europe San Diego, California and Sydney, Australia (Friday, 14 July 2017, AEST) – REVA Medical, Inc. (ASX: RVA), as part of its transition to commercial operations, today announced the hiring of a new chief financial officer, a vice president of European sales, and the ap

REVA MEDICAL FINANCING COMPLETE 6-16-17 (Current Report/Significant Event)

rva-8k20170616.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 16, 2017 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation)

Financing Completed Tranche 2 Cash Proceeds of US$13.3 Million Received

rva-ex9916.htm EXHIBIT 99.1 Financing Completed Tranche 2 Cash Proceeds of US$13.3 Million Received San Diego, California and Sydney, Australia (Monday, 19 June 2017, AEST) ? REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) announces that it has closed the second tranche and, therefore, has completed the financing transaction announced in April 2017 and approved by the Company?s shareholder

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 31, 2017 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File Nu

The FANTOM BRS Desaminotyrosine based polycarbonate backbone Strut thickness 125µm Sirolimus eluting for 3 months Full resorption within 3-4 years FANTOM II

rva-ex992143.pptx.htm REVA FANTOM II Performance and healing patterns by OCT Jo Simonsen, Emil Nielsen Holck, Didier Carri?, Nobert Frey, Matthias Lutz, Joachim Weber-Albers, Darius Dudek, Bernard Chevalier, Jouke Dijkstra, Jens Lassen, Jeffrey Anderson, Evald H?j Christiansen, Alexandre Abizaid, Niels Ramsing Holm On behalf of the FANTOM II investigators Niels Ramsing Holm Aarhus University Hospi

Speaker's name: Matthias Lutz I have the following potential conflicts of interest to report: Receipt of grants / research supports: REVA Medical, St. Jude Medical Receipt of honoraria or consultation fees: Abbott, St. Jude Medical Potential conflict

rva-ex9946.pptx.htm Studies beyond CE-mark: Fantom in long lesion & Multi-Vessel Disease Matthias Lutz University Medical Center Schleswig-Holstein, Campus Kiel, Germany Exhibit 99.4 Speaker's name: Matthias Lutz I have the following potential conflicts of interest to report: Receipt of grants / research supports: REVA Medical, St. Jude Medical Receipt of honoraria or consultation fees: Abbott, St

Potential conflicts of interest Speaker's name: Dr. Gregg W. Stone I have the following potential conflicts of interest to report: Consultant to REVA Medical, Inc.

rva-ex9957.pptx.htm The FANTOM Scaffold Expanding the use of Fantom BRS in worldwide markets: REVA?s global clinical trial programme and beyond Gregg W. Stone MD Columbia University Medical Center The Cardiovascular Research Foundation Exhibit 99.5 Potential conflicts of interest Speaker's name: Dr. Gregg W. Stone I have the following potential conflicts of interest to report: Consultant to REVA M

Regulation FD Disclosure, Financial Statements and Exhibits

8-K 1 rva-8k20170517.htm 8-K - PCR2017 SYMPOSIUM UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 17, 2017 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other j

Speaker's name: Lukasz Koltowski I have the following potential conflicts of interest to report: Receipt of grants / research supports: REVA Medical Receipt of honoraria or consultation fees: Medtronic, REVA Medical Potential conflicts of interest

EX-99.3 4 rva-ex9939.htm EX-99.3 Fantom: performance gains and clinical data for a next-generation BRS Lukasz Koltowski 1st Department of Cardiology Medical University of Warsaw Exhibit 99.3 Speaker's name: Lukasz Koltowski I have the following potential conflicts of interest to report: Receipt of grants / research supports: REVA Medical Receipt of honoraria or consultation fees: Medtronic, REVA M

REVA Symposium Showcases Clinical Data Company discusses positive long-term data, expanded clinical trials, and plans for growth

rva-ex9918.htm EXHIBIT 99.1 REVA Symposium Showcases Clinical Data Company discusses positive long-term data, expanded clinical trials, and plans for growth San Diego, California and Sydney, Australia (Thursday, 18 May 2017, AEST) ? Today at the Paris Course on Revascularization (?EuroPCR?), REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) sponsored a symposium entitled, Fantom: performance

REVA Announces Positive 12-Month Clinical Results 4.2% rate of MACE equivalent to best-in-class drug-eluting stents

rva-ex9916.htm EXHIBIT 99.1 REVA Announces Positive 12-Month Clinical Results 4.2% rate of MACE equivalent to best-in-class drug-eluting stents San Diego, California and Sydney, Australia (Wednesday, 17 May 2017, AEST) ? At the Paris Course on Revascularization (?EuroPCR?) being held this week in Paris, France, REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) announced sustained positive cl

Regulation FD Disclosure, Financial Statements and Exhibits

rva-8k20170516.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 16, 2017 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation)

Potential conflicts of interest Speaker's name: Dr. Alexandre Abizaid I have the following potential conflicts of interest to report: Consultant to REVA Medical, Inc.

rva-ex9927.pptx.htm The FANTOM II Study First Report for the 12-month clinical outcomes of the Fantom sirolimus-eluting bioresorbable scaffold Dr. Alexandre Abizaid Instituto Dante Pazzanese de Cardiologia Sao Paulo, Brazil EXHIBIT 99.2 Potential conflicts of interest Speaker's name: Dr. Alexandre Abizaid I have the following potential conflicts of interest to report: Consultant to REVA Medical, I

First Amendment to Amended and Restated Investors’ Rights Agreement dated September 24, 2014

rva-def14a20170531.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ?

RVA / REVA Medical, Inc. / Saints Capital Everest Lp - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* REVA Medical, Inc. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 76133E109 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design

JOINT FILING AGREEMENT

EX-99.1 2 d397294dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 16a-3(j) and Rule 13d-1(k)(1) and under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of Forms 3, 4, 5 and Schedules 13D and 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0.0001 per share, o

REVA MEDICAL 10-Q (Quarterly Report)

rva-10q20170331.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ?QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 or ?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54192 RE

REVA MEDICAL 2017 PRE 14A

rva-pre14a20170531.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ?

REVA MEDICAL 10-K/A 12/31/16 -- PART III (Annual Report)

10-K/A 1 rva-10ka20161231.htm 10-K/A 12/31/16 - PART III UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file nu

Appendix 4C Quarter Ended 31 March 2017

rva-ex9916.htm EXHIBIT 99.1 Appendix 4C Quarter Ended 31 March 2017 San Diego, California and Sydney, Australia (Friday, 28 April 2017 AEST) ? REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) is pleased to provide the attached Appendix 4C Quarterly Report for the quarter ended 31 March 2017. The Appendix 4C is unaudited. First Quarter Highlights During the first quarter of 2017, the Company

REVA MEDICAL 8-K APPENDIX 4C 3-31-17 (Current Report/Significant Event)

rva-8k20170427.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 27, 2017 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation

Convertible Note Deed dated April 22, 2017, by and among REVA Medical, Inc. and each person set out in Schedule 1 and Schedule 2

EX-4.1 2 rva-ex416.htm EX-4.1 EXHIBIT 4.1 Execution Version DATED 22 April 2017 (1) REVA MEDICAL, INC. - and - (2) Each person set out in schedule 1 AND SCHEDULE 2 CONVERTIBLE NOTE DEED WEST\275931237.13 CONTENTS BACKGROUND: 1 1. Subscription for, and issue of, Notes and Options1 2. Form of notes7 3. Certificates7 4. Registers8 5. Purpose9 6. Redemption and Conversion10 7. Adjustments to conversio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 22, 2017 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File

Stock Repurchase Agreement, dated April 22, 2017, by and between REVA Medical, Inc. and Medtronic, Inc.

EXHIBIT 10.1 STOCK REPURCHASE AGREEMENT This Stock Repurchase Agreement (this “Agreement”) is entered into as of April , 2017 (the “Effective Date”) by and between Reva Medical, Inc., a Delaware corporation (the “Company”), and Medtronic, Inc. (the “Stockholder”). R E C I T A L S WHEREAS, the Stockholder owns 1,732,260 shares of the Company’s Common Stock (the “Shares”). WHEREAS, the Company and t

Second Amendment to Convertible Note Deed and Subordination, dated April 22, 2017, by and among REVA Medical, Inc., Goldman Sachs International, and Senrigan Master Fund

EX-4.2 3 rva-ex427.htm EX-4.2 EXHIBIT 4.2 Executed Version SECOND AMENDMENT TO CONVERTIBLE NOTE DEED AND SUBORDINATION AGREEMENT THIS SECOND AMENDMENT TO CONVERTIBLE NOTE DEED AND SUBORDINATION AGREEMENT (this “Amendment”), is made as of April 22, 2017, by and among Reva Medical, Inc. (the “Company”), GOLDMAN SACHS INTERNATIONAL and SENRIGAN MASTER FUND (each a “Noteholder”), and is entered into w

Reva Medical 2017 FORM S-8

rva-s8.htm As filed with the Securities and Exchange Commission on February 27, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REVA Medical, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 33-0810505

Reva Medical 10-K (Annual Report)

rva-10k20161231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-54192 REVA MEDICAL, INC. (Exact name of regis

REVA MEDICAL SC 13G/A (Passive Acquisition of More Than 5% of Shares)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) REVA Medical, Inc. (Name of Issuer) Common Stock, par value 0.0001 per share (Title of Class of Securities) 76133E109 (CUSIP Number) July 7,

JOINT ACQUISTION AGREEMENT PURSUANT TO RULE 13d-1(k)

EX-99.1 2 a17-42221ex99d1.htm EX-99.1 EXHIBIT 99.1 JOINT ACQUISTION AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional j

RVA / REVA Medical, Inc. / Medtronic plc - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* REVA Medical, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 76133E 109 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to

Appendix 4C Quarter Ended 31 December 2016

rva-ex99159.htm EXHIBIT 99.1 Appendix 4C Quarter Ended 31 December 2016 San Diego, California and Sydney, Australia (Tuesday, 31 January 2017, AEDT) ? REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) is pleased to provide the attached Appendix 4C Quarterly Report for the quarter ended 31 December 2016. The Appendix 4C is unaudited. Fourth Quarter Highlights The Company completed an applicat

Financial Statements and Exhibits, Results of Operations and Financial Condition

rva-8k20170130.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 30, 2017 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporati

Reva Medical 10-Q (Quarterly Report)

rva-10q20160930.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54

Amendment #3 to Exclusive License Agreement #2 between Rutgers, The State University of New Jersey and REVA medical, Inc. dated July 1, 2010**

rva-ex10192.htm EXHIBIT 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETED ASTERISKS [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. ConfidentialPage # 1 AMENDMENT #3 TO EXCLUSIVE LICENSE AGREEMENT # 2 WHEREAS Reva Medical Inc. (?REVA?) and Rutgers,

Reva Medical 10-Q/A (Quarterly Report)

rva-10qa20160630.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fil

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

rva-8k20161105.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 5, 2016 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporati

Regulation FD Disclosure, Financial Statements and Exhibits

rva-8k20161031.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 31, 2016 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporati

Important Notice Not an Offer for Securities This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial product advic

rva-ex9927.pptx.htm October 31, 2016 Approaching Commercialization Exhibit 99.2 Important Notice Not an Offer for Securities This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial product advice nor take into account your investment objectives, taxation situation

Institutional Investor Briefing at TCT 2016

rva-ex9916.htm Exhibit 99.1 Institutional Investor Briefing at TCT 2016 Sydney, Australia and San Diego, California (Tuesday, 1 November 2016 AEDT) ? REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) is pleased to provide the presentation used today at its institutional investor briefing held during the Transcatheter Cardiovascular Therapeutics (?TCT?) conference in Washington, D.C. The brie

Regulation FD Disclosure, Financial Statements and Exhibits

rva-8k20161031.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 31, 2016 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporati

Disclosure Statement of Financial Interest Research Grants Consulting Fees/Honoraria Abbott Vascular Boston Scientific Elixir Medical Medtronic REVA Medical Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement o

rva-ex9927.pptx.htm FANTOM II: Six-Month Clinical and Angiographic Results With a Radiopaque Desaminotyrosine Polycarbonate-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease Dr. Alexandre Abizaid Instituto Dante Pazzanese de Cardiologia Sao Paulo, Brazil On behalf of the FANTOM II investigators FANTOM II Exhibit 99.2 Disclosure Statement of Financial

Disclosure Statement of Financial Interest Travel grants Institutional research grant St. Jude Medical REVA medical Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) li

rva-ex9938.pptx.htm Performance and healing patterns after implantation of a novel sirolimus-eluting bioresorbable scaffold Jo Simonsen, Emil Nielsen Holck, Didier Carri?, Nobert Frey, Matthias Lutz, Joachim Weber-Albers, Darius Dudek, Bernard Chevalier, Jouke Dijkstra, Jens Lassen, Jeffrey Anderson, Evald H?j Christiansen, Alexandre Abizaid, Niels Ramsing Holm Six-month OCT follow-up in the FANTO

REVA Releases Positive Data for Fantom at TCT

rva-ex9916.htm Exhibit 99.1 REVA Releases Positive Data for Fantom at TCT Sydney, Australia and San Diego, California (Tuesday, 1 November 2016 AEDT) ?REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) is pleased to announce that it released final six-month safety data on the complete patient population enrolled in the FANTOM II clinical trial at the Transcatheter Cardiovascular Therapeutics

Appendix 4C Quarter Ended 30 September 2016

rva-ex9916.htm EXHIBIT 99.1 Appendix 4C Quarter Ended 30 September 2016 San Diego, California and Sydney, Australia (Friday, 28 October 2016, AEDT) ? REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) is pleased to provide the attached Appendix 4C Quarterly Report for the quarter ended 30 September 2016. The Appendix 4C is unaudited. Third Quarter Highlights The Company completed an applicati

Financial Statements and Exhibits, Results of Operations and Financial Condition

rva-8k20161027.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 27, 2016 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporati

Current Report

rva-8k20160926.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: September 26, 2016 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorpora

Reva Medical 10-Q (Quarterly Report)

rva-10q20160630.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54192 R

Submission of CE Mark Application

rva-ex9916.htm EXHIBIT 99.1 Submission of CE Mark Application Sydney, Australia and San Diego, California (Wednesday, 3 August 2016 AEST) ? REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) is pleased to announce that it has submitted an application for CE Marking of its Fantom scaffold, following completion of clinical data analyses and required testing. The regulatory approval process gene

Regulation FD Disclosure, Financial Statements and Exhibits

rva-8k20160802.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 2, 2016 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation

Appendix 4C Quarter Ended 30 June 2016

rva-ex9916.htm EXHIBIT 99.1 Appendix 4C Quarter Ended 30 June 2016 San Diego, California and Sydney, Australia (Friday, 29 July 2016, AEST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) is pleased to provide the attached Appendix 4C Quarterly Report for the quarter ended 30 June 2016. The Appendix 4C is unaudited. Second Quarter Highlights The Company is continuing clinical testing, co

Financial Statements and Exhibits, Results of Operations and Financial Condition

rva-8k20160728.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 28, 2016 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation)

Current Report

rva-8k20160525.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 25, 2016 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation)

Potential conflicts of interest Gregg W. Stone Consultant to Reva

rva-ex9928.pptx.htm Advantages of Desaminotyrosine Polycarbonate Polymers Gregg W. Stone MD Columbia University Medical Center The Cardiovascular Research Foundation EXHIBIT 99.2 Potential conflicts of interest Gregg W. Stone Consultant to Reva Fantom BRS Polymer Polymer structure Material and scaffold characteristics Biologic safety Clinical advantages Fantom Polymer Polymer Structure Fantom Poly

Potential conflicts of interest Speaker's name: Dr. Norbert Frey I have the following potential conflicts of interest to report: Consultant to REVA Medical, Inc.

rva-ex993_9.pptx.htm FANTOM II trial: Clinical results from the Fantom® Sirolimus-Eluting BRS Norbert Frey, MD University of Kiel, Germany EXHIBIT 99.3 Potential conflicts of interest Speaker's name: Dr. Norbert Frey I have the following potential conflicts of interest to report: Consultant to REVA Medical, Inc. Fantom Bioresorbable Scaffold Clinical Program Overview FANTOM I (Pilot Trial) 7 patie

REVA Symposium at EuroPCR 2016

rva-ex99110.htm EXHIBIT 99.1 REVA Symposium at EuroPCR 2016 San Diego, California and Sydney, Australia (Thursday, 19 May 2016, AEST) ? Today at the Paris Course on Revascularization (?EuroPCR?), REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) sponsored a symposium entitled, Advancing BRS through Innovative Biomaterials, where information about the performance and key advantages of the Com

Regulation FD Disclosure, Financial Statements and Exhibits

rva-8k20160518.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 18, 2016 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation)

Potential conflicts of interest Speaker's name: Dr. Alexandre Abizaid I have the following potential conflicts of interest to report: Consultant to REVA Medical, Inc.

rva-ex9927.pptx.htm Fantom? Bioresorbable Sirolimus-Eluting Scaffold EXHIBIT 99.2 Potential conflicts of interest Speaker's name: Dr. Alexandre Abizaid I have the following potential conflicts of interest to report: Consultant to REVA Medical, Inc. Fantom Bioresorbable Scaffold Fantom? (REVA Medical) Sirolimus-Eluting Bioresorbable Scaffold Desaminotyrosine Polycarbonate Key Scaffold Features Comp

Positive Clinical Results for Fantom

rva-ex9916.htm EXHIBIT 99.1 Positive Clinical Results for Fantom San Diego, California and Sydney, Australia (Wednesday, 18 May 2016, AEST) ? At the Paris Course on Revascularization (?EuroPCR?) being held this week in Paris, France, REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) announced positive six-month results from the first cohort of patients in the Company?s FANTOM II clinical tri

Regulation FD Disclosure, Financial Statements and Exhibits

rva-8k20160517.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 17, 2016 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation)

RVA / REVA Medical, Inc. 10-Q - Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54192 REVA MEDICAL, INC. (

REVA MEDICAL DEF 14A

DEF 14A 1 d183528ddef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ; Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rul

Appendix 4C Quarter Ended 31 March 2016

rva-ex99115.htm EXHIBIT 99.1 Appendix 4C Quarter Ended 31 March 2016 San Diego, California and Sydney, Australia (Friday, 29 April 2016, AEST) ? REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) is pleased to provide the attached Appendix 4C Quarterly Report for the quarter ended 31 March 2016. The Appendix 4C is unaudited. First Quarter Highlights During the first quarter of 2016, the Compa

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 28, 2016 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File

REVA MEDICAL PRE 14A

rva-pre14a20160525.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) o

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 22, 2016 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File

RVA / REVA Medical, Inc. 10-K - Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-54192 REVA MEDICAL, INC. (Exact name of registrant as specified i

Employment Agreement, dated January 18, 2016 by and between REVA Medical, Inc. and Richard M. Kimes*

Exhibit 10.25 January 4, 2016 Richard Kimes 2400 5th Avenue, Unit 436 San Diego, CA 92101 Dear Rick, I am delighted to confirm the offer of employment that we made and you verbally accepted. REVA Medical has offered and you have accepted the position of Sr. VP, Operations. In this position you will be a valuable member of the REVA team and will report directly to Reggie Groves. Starting Date: Your

REVA MEDICAL S-8

S-8 1 rva-s820160310.htm S-8 As filed with the Securities and Exchange Commission on March 10, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REVA Medical, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organizat

First Amendment to Convertible Note Deed, dated February 11, 2016, by and among REVA Medical, Inc., Goldman Sachs International, and Senrigan Master Fund

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

REVA MEDICAL 8-K (Current Report/Significant Event)

rva-8k20160225.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 25, 2016 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporat

Preliminary Final Report on Appendix 4E Year Ended 31 December 2015

rva-ex9916.htm EXHIBIT 99.1 Preliminary Final Report on Appendix 4E Year Ended 31 December 2015 Sydney, Australia and San Diego, California (Friday, 26 February 2016, AEDT) ? REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) is pleased to release its preliminary financial report for the year ended 31 December 2015 (the ?Results?) in the accompanying Appendix 4E. These Results are currently b

REVA MEDICAL PRE 14A

PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

RVA / REVA Medical, Inc. / Senrigan Capital Group Ltd - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)* REVA Medical, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 76133E109 (CUSIP Number) Octo

JOINT ACQUISTION AGREEMENT PURSUANT TO RULE 13d-1(k)

EX-99.1 2 a16-47931ex99d1.htm EX-99.1 EXHIBIT 99.1 JOINT ACQUISTION AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional j

Clinical Enrollment Progress Anticipated $11.4 Million Cash Receipt

rva-ex9917.htm EXHIBIT 99.1 Clinical Enrollment Progress and Anticipated $11.4 Million Cash Receipt San Diego, California and Sydney, Australia (Thursday, 11 February 2016, AEDT) ? REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) is pleased to announce that it has enrolled over 200 patients in a clinical study of its Fantom? sirolimus-eluting bioresorbable coronary scaffold and continues on

FIRST AMENDMENT TO CONVERTIBLE NOTE DEED

rva-ex416.htm EXHIBIT 4.1 FIRST AMENDMENT TO CONVERTIBLE NOTE DEED THIS FIRST AMENDMENT TO CONVERTIBLE NOTE DEED (this ?Amendment?), is made as of February 11, 2016, by and among REVA Medical, Inc. (the ?Company?), and Goldman Sachs International and Senrigan Master Fund (the ?Noteholders?), and is entered into with respect to the Convertible Note Deed, dated September 25, 2014, by and among the C

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

rva-8k20160210.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 10, 2016 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporat

REVA MEDICAL SC 13G/A AMENDMENT NO. 2 (Passive Acquisition of More Than 5% of Shares)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* REVA Medical, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 76133E 109 (CUSIP Number) January 26, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to

Appendix 4C Quarter Ended 31 December 2015

rva-ex99186.htm EXHIBIT 99.1 Appendix 4C Quarter Ended 31 December 2015 San Diego, California and Sydney, Australia (Friday, 29 January 2016, AEDT) ? REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) is pleased to provide the attached Appendix 4C Quarterly Report for the quarter ended 31 December 2015. The Appendix 4C is unaudited. Fourth Quarter Highlights During the fourth quarter of 2015,

REVA MEDICAL 8-K (Current Report/Significant Event)

rva-8k20160128.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 28, 2016 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporati

Important Notice Not an Offer for Securities This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial product advic

rva-ex9916.pptx.htm January 14, 2016 J.P. Morgan 2016 Healthcare Conference Exhibit 99.1 Important Notice Not an Offer for Securities This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial product advice nor take into account your investment objectives, taxation

Regulation FD Disclosure, Financial Statements and Exhibits

8-K 1 rva-8k20160114.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 14, 2016 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

10-Q 1 rva-10q20150930.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file nu

Exclusive License Agreement Number 2 between Rutgers, The State University of New Jersey and REVA Medical, Inc. dated July 1, 2010**

Exhibit 10.2 EXCLUSIVE LICENSE AGREEMENT NUMBER Between REVA Medical, Inc. and RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY {00055541.1 / 002795} EXCLUSIVE LICENSE AGREEMENT NUMBER 2 THIS Exclusive License Agreement Number 2 (the "Agreement") is made and is effective as of the 1st day of July 2010, (the “Effective Date”) by and between Rutgers, The State University Of New Jersey, having its statewi

REVA MEDICAL 8-K (Current Report/Significant Event)

rva-8k20151029.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 29, 2015 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporati

Appendix 4C Quarter Ended 30 September 2015

rva-ex99121.htm EXHIBIT 99.1 Appendix 4C Quarter Ended 30 September 2015 San Diego, California and Sydney, Australia (Friday, 30 October 2015, AEDT) ? REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) is pleased to provide the attached Appendix 4C Quarterly Report for the quarter ended 30 September 2015. The Appendix 4C is unaudited. Third Quarter Highlights Effective 23 September 2015, the

REVA MEDICAL 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 15, 2015 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission Fil

Positive Initial Results for Fantom Released at TCT

Exhibit 99.1 Positive Initial Results for Fantom Released at TCT San Diego, California and Sydney, Australia (Friday, 16 October 2015, AEST) ? REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) is pleased to announce that Dr. J. Ribamar Costa from the Institute Dante Pazzanese of Cardiology, in Sao Paulo, Brazil, presented results from REVA?s clinical trial program for its Fantom? sirolimus-e

Fantom Presentation at Next-Generation Session

Exhibit 99.1 Fantom Presentation at Next-Generation Session San Diego, California and Sydney, Australia (Thursday, 15 October 2015, AEST) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) is pleased to announce that Dr. J. Ribamar Costa, from Dante Pazzanese of Cardiology, in Sao Paulo, Brazil, is presenting performance data on REVA’s Fantom® sirolimus-eluting bioresorbable scaffold at the

REVA MEDICAL 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 14, 2015 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction (Commission (I.R.S. Employer of i

REVA MEDICAL 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 1, 2015 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File

EXECUTIVE EMPLOYMENT AGREEMENT

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this ?Agreement?) is made effective as of September 21, 2015 (the ?Effective Date?), by and between REVA Medical, Inc. (the ?Company?) and Regina Groves (the ?Executive?). The parties agree as follows: 1. Employment. The Company hereby employs Executive, and Executive hereby accepts such employment, upon the terms and

REVA Appoints Regina Groves as Chief Executive Officer

Exhibit 99.1 REVA Appoints Regina Groves as Chief Executive Officer San Diego, California (Thursday, August 20, 2015, PDT) ? REVA Medical, Inc. (ASX: RVA) is pleased to announce the appointment of Regina Groves as its Chief Executive Officer, effective September 21, 2015. Ms. Groves will replace Robert Stockman, who will remain as non-executive Chairman of the Board of Directors. Ms. Groves brings

REVA MEDICAL 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 20, 2015 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54192 REV

Appendix 4C Quarter Ended 30 June 2015

Exhibit 99.1 Appendix 4C Quarter Ended 30 June 2015 San Diego, California and Sydney, Australia (Friday, 31 July 2015, AEST) ? REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) is pleased to provide the attached Appendix 4C Quarterly Report for the quarter ended 30 June 2015. The Appendix 4C is unaudited. Second Quarter Highlights During the second quarter of 2015, the Company?s operating ac

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 30, 2015 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File N

Submission of Matters to a Vote of Security Holders

8-K 1 a15-1295318k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 27, 2015 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorpo

REVA MEDICAL 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 22, 2015 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File Nu

Initial Clinical Results for Fantom Scaffold

Exhibit 99.1 Initial Clinical Results for Fantom Scaffold San Diego, California and Sydney, Australia (Friday, 22 May 2015, AEST) ? REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) released initial clinical data on a subset of patients treated with the FantomTM sirolimus-eluting bioresorbable scaffold at the Paris Course on Revascularization (?EuroPCR?). Reporting on the results was Dr. Ale

Regulation FD Disclosure, Financial Statements and Exhibits

8-K 1 a15-1164018k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 14, 2015 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorpo

REVA Undertakes Search for Chief Executive Officer Robert Stockman to Remain Chairman

Exhibit 99.1 REVA Undertakes Search for Chief Executive Officer Robert Stockman to Remain Chairman San Diego, California and Sydney, Australia (Thursday, 14 May 2015, AEST) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) announces today that in preparation for the next stage of the Company’s development, the board of directors has initiated a search for its future Chief Executive Officer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54192 RE

Appendix 4C Quarter Ended 31 March 2015

Exhibit 99.1 Appendix 4C Quarter Ended 31 March 2015 San Diego, California and Sydney, Australia (Thursday, 30 April 2015, AEST) ? REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) is pleased to provide the attached Appendix 4C Quarterly Report for the quarter ended 31 March 2015. The Appendix 4C is unaudited. First Quarter Highlights During the first quarter of 2015, the Company?s operating

REVA MEDICAL DEF 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 30, 2015 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File

REVA MEDICAL PRE 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14

REVA MEDICAL S-8

As filed with the Securities and Exchange Commission on March 30, 2015 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

10-K 1 a15-1762110k.htm 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-54192 REVA MEDICAL

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 25, 2015 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission File

Scott Huennekens Appointed to Board of Directors

Exhibit 99.1 Scott Huennekens Appointed to Board of Directors San Diego, California and Sydney, Australia (Thursday, 26 March 2015, AEDT) ? REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) today announced that Scott Huennekens, a recognized business executive in the medical device industry, has been appointed to its Board of Directors as a non-executive director. Scott Huennekens most recen

Financial Statements and Exhibits, Other Events

8-K 1 a15-690918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 16, 2015 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorp

Initiation of FANTOM II Clinical Trial Live Case Implant at ACC

Exhibit 99.1 Initiation of FANTOM II Clinical Trial and Live Case Implant at ACC San Diego, California and Sydney, Australia (Monday, 16 March 2015, AEDT) ? REVA Medical, Inc. (ASX: RVA) (?REVA? or the ?Company?) is pleased to announce the initiation of patient enrollment in the FANTOM II clinical trial of its Fantom? sirolimus-eluting bioresorbable scaffold. The Fantom scaffold, made from REVA?s

Preliminary Final Report on Appendix 4E Year Ended 31 December 2014

EX-99.1 2 a15-55701ex99d1.htm EX-99.1 Exhibit 99.1 Preliminary Final Report on Appendix 4E Year Ended 31 December 2014 Sydney, Australia and San Diego, California (Friday, 27 February 2015, AEDT) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) is pleased to release its preliminary financial report for the year ended 31 December 2014 (the “Results”) in the accompanying Appendix 4E. These

Preliminary Final Report Appendix 4E Year Ended 31 December 2014 HEAD OFFICE: 5751 Copley Drive, San Diego, CA 92111 · +1 (858) 966-3000 · +1 (858) 966-3099 (FAX)· www.revamedical.com AUSTRALIAN OFFICE: Suite 4, Level 14, 6 O’Connell Street, Sydney N

EX-99.2 3 a15-55701ex99d2.htm EX-99.2 Exhibit 99.2 Preliminary Final Report Appendix 4E Year Ended 31 December 2014 HEAD OFFICE: 5751 Copley Drive, San Diego, CA 92111 · +1 (858) 966-3000 · +1 (858) 966-3099 (FAX)· www.revamedical.com AUSTRALIAN OFFICE: Suite 4, Level 14, 6 O’Connell Street, Sydney NSW 2000 · +61 2 9237 2800 ARBN 146 505 777 · REVA Medical, Inc., is a foreign company incorporated

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 27, 2015 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction (Commission (I.R.S. Employer of

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 23, 2015 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission Fi

Presentations at CRT Conference

Exhibit 99.1 Presentations at CRT Conference San Diego, California and Sydney, Australia (Tuesday, 24 February 2015, AEDT) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) is pleased to announce that Dr. Alexandre Abizaid, Director of Invasive Cardiology at Institute Dante Pazzanese of Cardiology, in Sao Paulo, Brazil, presented information regarding the Company’s bioresorbable scaffold p

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 28, 2015 (Date of earliest event reported) REVA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-54192 33-0810505 (State or other jurisdiction of incorporation) (Commission Fil